Adlai Nortye (ANL) Competitors $1.57 +0.06 (+3.97%) Closing price 07/15/2025 03:59 PM EasternExtended Trading$1.53 -0.04 (-2.55%) As of 07/15/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock ANL vs. LRMR, CRGX, DSGN, SLS, KOD, MDWD, SCPH, ACIU, ELDN, and TVRDShould you be buying Adlai Nortye stock or one of its competitors? The main competitors of Adlai Nortye include Larimar Therapeutics (LRMR), CARGO Therapeutics (CRGX), Design Therapeutics (DSGN), SELLAS Life Sciences Group (SLS), Kodiak Sciences (KOD), MediWound (MDWD), scPharmaceuticals (SCPH), AC Immune (ACIU), Eledon Pharmaceuticals (ELDN), and Tvardi Therapeutics (TVRD). These companies are all part of the "pharmaceutical products" industry. Adlai Nortye vs. Its Competitors Larimar Therapeutics CARGO Therapeutics Design Therapeutics SELLAS Life Sciences Group Kodiak Sciences MediWound scPharmaceuticals AC Immune Eledon Pharmaceuticals Tvardi Therapeutics Larimar Therapeutics (NASDAQ:LRMR) and Adlai Nortye (NASDAQ:ANL) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, institutional ownership, valuation, dividends, analyst recommendations and media sentiment. Do institutionals & insiders hold more shares of LRMR or ANL? 91.9% of Larimar Therapeutics shares are owned by institutional investors. Comparatively, 35.2% of Adlai Nortye shares are owned by institutional investors. 4.5% of Larimar Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Does the media refer more to LRMR or ANL? In the previous week, Adlai Nortye had 1 more articles in the media than Larimar Therapeutics. MarketBeat recorded 2 mentions for Adlai Nortye and 1 mentions for Larimar Therapeutics. Adlai Nortye's average media sentiment score of 1.24 beat Larimar Therapeutics' score of 0.94 indicating that Adlai Nortye is being referred to more favorably in the news media. Company Overall Sentiment Larimar Therapeutics Positive Adlai Nortye Positive Which has more risk & volatility, LRMR or ANL? Larimar Therapeutics has a beta of 0.86, indicating that its share price is 14% less volatile than the S&P 500. Comparatively, Adlai Nortye has a beta of -0.95, indicating that its share price is 195% less volatile than the S&P 500. Is LRMR or ANL more profitable? Adlai Nortye's return on equity of 0.00% beat Larimar Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Larimar TherapeuticsN/A -52.48% -46.08% Adlai Nortye N/A N/A N/A Do analysts prefer LRMR or ANL? Larimar Therapeutics currently has a consensus target price of $18.50, suggesting a potential upside of 485.44%. Adlai Nortye has a consensus target price of $9.00, suggesting a potential upside of 473.25%. Given Larimar Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Larimar Therapeutics is more favorable than Adlai Nortye.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Larimar Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11Adlai Nortye 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has higher earnings and valuation, LRMR or ANL? Adlai Nortye has higher revenue and earnings than Larimar Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLarimar TherapeuticsN/AN/A-$80.60M-$1.49-2.12Adlai Nortye$5M11.59-$51.87MN/AN/A SummaryLarimar Therapeutics beats Adlai Nortye on 7 of the 13 factors compared between the two stocks. Get Adlai Nortye News Delivered to You Automatically Sign up to receive the latest news and ratings for ANL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ANL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANL vs. The Competition Export to ExcelMetricAdlai NortyeMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$55.72M$2.96B$5.62B$9.29BDividend YieldN/A2.43%4.25%4.03%P/E RatioN/A20.2228.5719.58Price / Sales11.59290.24423.3293.40Price / CashN/A43.1536.0257.93Price / Book2.287.568.135.54Net Income-$51.87M-$55.11M$3.24B$257.73M7 Day Performance0.09%3.81%0.16%-0.08%1 Month Performance-7.05%11.60%5.95%8.09%1 Year Performance-57.22%-2.11%26.09%13.02% Adlai Nortye Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANLAdlai Nortye2.1024 of 5 stars$1.57+4.0%$9.00+473.2%-55.0%$55.72M$5M0.00127LRMRLarimar Therapeutics1.9943 of 5 stars$3.43+7.3%$18.50+438.9%-70.4%$219.88MN/A-2.3030CRGXCARGO Therapeutics2.2153 of 5 stars$4.56+3.8%$15.00+229.3%-73.8%$210.03MN/A-0.99116High Trading VolumeDSGNDesign Therapeutics0.533 of 5 stars$3.69+4.1%$4.00+8.5%-12.5%$209.20MN/A-3.7240SLSSELLAS Life Sciences Group0.3595 of 5 stars$2.10-3.5%N/A+74.3%$208.04M$1M-5.4910KODKodiak Sciences4.0276 of 5 stars$3.94+6.2%$9.00+128.4%+62.5%$207.87MN/A-1.0990Gap UpMDWDMediWound1.6119 of 5 stars$19.23-0.2%$31.80+65.4%-2.0%$207.84M$19.21M-9.2080News CoverageSCPHscPharmaceuticals4.3829 of 5 stars$3.93+1.8%$14.00+256.2%-7.2%$207.47M$36.33M-2.0630Positive NewsACIUAC Immune2.1588 of 5 stars$2.02+1.6%$12.00+493.8%-44.4%$203.83M$31.02M-3.50140News CoveragePositive NewsAnalyst RevisionGap UpELDNEledon Pharmaceuticals1.8273 of 5 stars$3.41+9.6%$9.00+163.9%+47.5%$202.39MN/A-1.6110Positive NewsAnalyst RevisionGap UpTVRDTvardi TherapeuticsN/A$21.510.0%$71.50+232.4%N/A$201.33M$7.14M0.0080News CoverageAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies Larimar Therapeutics Alternatives CARGO Therapeutics Alternatives Design Therapeutics Alternatives SELLAS Life Sciences Group Alternatives Kodiak Sciences Alternatives MediWound Alternatives scPharmaceuticals Alternatives AC Immune Alternatives Eledon Pharmaceuticals Alternatives Tvardi Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ANL) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adlai Nortye Ltd. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Adlai Nortye With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ANL Stock Alerts